Sarah Psutka, MD, on phase 3 trial of padeliporfin VTP therapy in UTUC
Published: January 2nd 2025 | Updated: January 2nd 2025“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.